You are currently viewing the abstract.View Full Text
Myriad bi-specific proteins have been developed that recognize two different clinical targets, with the goal of achieving enhanced therapeutic effects as compared with proteins that interact with only one target. These engineered proteins are starting to enter clinical testing for a variety of biomedical applications, particularly cancer treatment.
Citation: J. R. Cochran, Engineered proteins pull double duty. Sci. Transl. Med. 2, 17ps5 (2010).
- Copyright © 2010, American Association for the Advancement of Science